Publication | Open Access
Proton‐Driven Transformable <sup>1</sup>O<sub>2</sub>‐Nanotrap for Dark and Hypoxia Tolerant Photodynamic Therapy
49
Citations
29
References
2022
Year
Despite the clinical potential, photodynamic therapy (PDT) relying on singlet oxygen (<sup>1</sup> O<sub>2</sub> ) generation is severely limited by tumor hypoxia and endosomal entrapment. Herein, a proton-driven transformable <sup>1</sup> O<sub>2</sub> -nanotrap (ANBDP NPs) with endosomal escape capability is presented to improve hypoxic tumor PDT. In the acidic endosomal environment, the protonated <sup>1</sup> O<sub>2</sub> -nanotrap ruptures endosomal membranes via a "proton-sponge" like effect and undergoes a drastic morphology-and-size change from nanocubes (≈94.1 nm in length) to nanospheres (≈12.3 nm in diameter). Simultaneously, anthracenyl boron dipyrromethene-derived photosensitizer (ANBDP) in nanospheres transforms to its protonated form (ANBDPH) and switches off its charge-transfer state to achieve amplified <sup>1</sup> O<sub>2</sub> photogeneration capability. Upon 730 nm photoirradiation, ANBDPH prominently produces <sup>1</sup> O<sub>2</sub> and traps generated-<sup>1</sup> O<sub>2</sub> in the anthracene group to form endoperoxide (ANOBDPH). Benefitting from the hypoxia-tolerant <sup>1</sup> O<sub>2</sub> -release property of ANOBDPH in the dark, the <sup>1</sup> O<sub>2</sub> -nanotrap brings about sustained therapeutic effect without further continuous irradiation, thereby achieving remarkable antitumor performance.
| Year | Citations | |
|---|---|---|
Page 1
Page 1